BRIEF-Interim data support safety and efficacy of Pharming Group's RUCONEST
June 1 (Reuters) - Pharming Group NV :
* Announces interim results from the ongoing phase II pediatric clinical trial of RUCONEST
* Interim data from ongoing pediatric clinical trial and results from a clinical immunology study support safety and efficacy of RUCONEST
* Several abstracts presented demonstrate Pharming's ongoing commitment to advance innovative science in Hereditary Angioedema (HAE)
* "These data add to our clinical database and post-marketing experience that demonstrate a very low risk of allergy with rhC1INH exposure" - Chief Operating officer Source text for Eikon: Further company coverage: (Gdynia Newsroom)
© Thomson Reuters 2017 All rights reserved.